Full Generic Medicine Info
Dosage/Direction for Use

Adult: Initially, 5-10 mg daily. Start w/ 2.5 mg once daily if used w/ other diuretics or antihypertensives. Max: 20 mg daily.
Renal impairment: Severe: Avoid use.
Should be taken with food.
Hyperkalaemia, Addison's disease, anuria, acute or chronic renal insufficiency, diabetic nephropathy.
Special Precautions
Patient w/ DM, at risk of metabolic or resp acidosis. Renal and hepatic impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor serum electrolytes, BP and renal function.
Adverse Reactions
Abdominal pain, GI bleeding, thirst, dry mouth, diarrhoea, constipation, anorexia, jaundice, flatulence, dyspepsia, vomiting, nausea, angina, arrhythmias, palpitation, postural hypotension, dyspnoea, cough, nasal congestion, confusion, headache, insomnia, weakness, tremor, agitation, dizziness, malaise, paraesthesia, encephalopathy, urinary disturbances, sexual dysfunction, hyperkalaemia, muscle cramps, arthralgia, raised intraocular pressure, visual disturbance, tinnitus, alopecia, pruritus, rash.
B D if used in gestational HTN.
Drug Interactions
Increased risk of hyperkalaemia w/ other K-sparing diuretics, K supplements, angiotensin II receptor antagonists, ACE inhibitors, trilostane. Increased risk of nephrotoxicity w/ ciclosporin and NSAIDs. Severe hyponatraemia may occur w/ thiazide or chlorpropamide. May reduce ulcer-healing properties w/ carbenoxolone. May enhance the effect of other antihypertensives.
Food Interaction
Food reduces bioavailability.
Lab Interference
May falsely increase serum digoxin levels done by radioimmunoassay.
Amiloride is a weak diuretic which acts mainly on the distal renal tubules. It increases the excretion of Na and reduces the excretion of K. It diminishes kaliuretic effects of other diuretics, and may produce an additional natriuretic effect.
Onset: 2 hr.
Duration: 24 hr.
Absorption: Incompletely absorbed from the GI tract. Bioavailability is reduced by food. Bioavailability: Approx 50%. Time to peak plasma concentration: Approx 3-4 hr.
Distribution: Widely distributed in the tissues. Volume of distribution: 350-380 L. Plasma protein binding: 23%.
Metabolism: Not metabolised.
Excretion: Via urine (as unchanged drug). Plasma half-life: 6-9 hr; terminal half-life: ≥20 hr.
Oral: Store between 15-30°C.
CIMS Class
ATC Classification
C03DB01 - amiloride ; Belongs to the class of other potassium-sparing agents. Used as diuretics.
Disclaimer: This information is independently developed by CIMS based on amiloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in